The drug company Corbus Pharmaceuticals will start its next Phase 2 clinical trial to test a potential inflammation-targeting drug in people with cystic fibrosis in the first quarter of 2018.
Icagen Inc. will focus on drug discovery, screening for compounds that could suppress nonsense mutations, and using computer modeling to identify molecules that are suitable to be developed into drugs.
New Effort Will Search for Potential Therapies Targeting the Most Common Mutation of Cystic Fibrosis
This week, Congress approved a budget resolution that will allow lawmakers to make certain changes to the Affordable Care Act and Medicaid.
Today, the Cystic Fibrosis Foundation announced that it has awarded up to $400,000 to Life Edit Therapeutics Inc. to explore the application of their unique gene editing technology in CF.
Today, the Cystic Fibrosis Foundation announced that it will invest up to $8.4 million in SpliSense's Series B funding round to develop an antisense oligonucleotide therapy for people with cystic fibrosis who have splicing mutations and potentially other rare mutations.
The Cystic Fibrosis Foundation is awarding up to $15.9 million in additional funding to Eloxx Pharmaceuticals Inc. to expand clinical studies of ELX-02, a potential therapy for people with CF who have nonsense mutations.